Abstract：【Objective】The aim of this study was to investigate the expression and clinical significance of miR-34b and target gene cyclin-dependent kinase 6 (CDK6) in osteosarcoma, and to provide a new therapeutic approach for gene therapy of osteosarcoma. 【Methods】A total of 51 cases of osteosarcoma patients who underwent surgical resection in our hospital from March 12, 2016 to March 12, 2017 were selected as the subject of study. There were 51 cases of osteosarcoma and corresponding 51 cases of normal bone tissue (At least 2 cm from the edge of the cancer tissue) were collected. The levels of miR-34b and CDK6 mRNA in osteosarcoma and adjacent normal tissues were detected by qRT-PCR. The expression of CDK6 protein in osteosarcoma and adjacent normal tissues was detected by immunohistochecmistry (S-P method). The relationship between the expression of miR-34b and CDK6 was analyzed, and the correlation between the expression of the two genes and their clinicopathological features of osteosarcom was analyzed as well. 【Results】 The expression level of miR-34b mRNA in osteosarcoma tissue was 0.34±0.16, which was significantly lower than that in adjacent tissues (1.06±0.13); the difference was statistically significant (Z=24.942,P=0.000). The expression level of CDK6 mRNA in osteosarcoma tissue was 4.37±0.46, which was significantly higher than that in adjacent tissue (1.03±0.12, Z=50.174, P=0.000). The positive expression rate of CDK6 protein in osteosarcoma tissue was 78.43%, which was significantly higher than that in adjacent tissue 17.65%(χ2=37.744,P=0.000). The expression of miR-34b and CDK6 was negatively correlated (r=-0.483, P=0.000). The expression of miR-34b and CDK6 were not significantly correlated with age, sex, tumor size and tumor location of osteosarcoma patients (Z=0.203、0.384、0.230、0.135;P=0.840、0.703、0.819、0.894.χ2=0.644、0.051、2.403、0.746;P=0.422、0.821、0.121、0.689), while itwas closely related to Enneking staging and tumor metastasis (Z=2.509、3.962, P=0.016、0.000;χ2=6.451、4.217,P=0.040、0.040). 【Conclusion】miR-34b may be involved in the development of osteosarcoma through regulating the expression of target gene CDK6 gene.
[1] 牛晓辉. 2017版NCCN《骨肿瘤临床实践指南》更新与解读[J].中华外科杂志, 2017, 55(1):41-43. [2] 康晓征,黄真,石安辉,等. 骨肉瘤肺转移存在诊断治疗不足—中国骨肉瘤肺转移多学科诊疗现况调查[J].中国肺癌杂志,2016, 19(03):153-160. [3] 宋秀军. miR-34b表达调控及其在肿瘤发生中作用的研究进展[J].肿瘤研究与临床, 2014, 26(12):851-853. [4] 殷玉敬. MiR-34b和miR-155在非小细胞肺癌中的表达及临床意义[J].现代肿瘤医学, 2015, 23(14):1993-1996. [5] 曾令成.细胞周期蛋白依赖性激酶6在脑星型细胞瘤中的表达[J].中华实验外科杂志, 2015, 32(9):251-253. [6] 姚斌, 夏冰, 李觅,等. 367例原发性骨肉瘤流行病学及临床病理分析[J].临床外科杂志, 2014, 22(2):119-121. [7] Daw NC, Chou AJ, Jaffe N,et al. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review[J].British Journal of Cancer,2015, 112(2):278-282. [8] Liu R, Jacobs D I, Hansen J, et al. Aberrant methylation of miR-34b is associated with long-term shiftwork: a potential mechanism for increased breast cancer susceptibility.[J].Cancer Causes & Control,2015, 26(2):171-178. [9] 凌晨,刘蜀,王勇,等. CDK6在早期卵巢癌中表达及其临床意义[J].南方医科大学学报,2016, 36(9):1271-1275. [10] Tian Q, Jia J, Ling S, et al. A causal role for circulating miR-34b in osteosarcoma[J].Eur J Surg Oncol,2014, 40(1):67-69.
2018, Vol. 35 
